Product Information

VERAPAMIL ER 180 MG TABLET is a generic product labeled by Nivagen Pharmaceuticals Inc., priced at $0.1914 per EA under NDC 75834015805. Its NADAC has been published 242 times since Dec 8, 2021.

FDA first approved this application on May 5, 2017. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

VERAPAMIL ER 180 MG TABLET

VERAPAMIL HYDROCHLORIDE
$0.1914per EA

Strength

180 mg/1

NDC

75834015805

Classification

Generic

Dosage Form

TABLET

Route

ORAL

Effective Date

7/22/2026

Active Ingredients

VERAPAMIL HYDROCHLORIDE

Approval Type

Generic (ANDA)

FDA Application

ANDA206173

FDA Approved

5/5/2017

TE Code

AB

On Market Since

5/15/2019

Pharmacological Classes

Calcium Channel Antagonists
Calcium Channel Blocker
Cytochrome P450 3A Inhibitors
Cytochrome P450 3A4 Inhibitors
P-Glycoprotein Inhibitors

Price Statistics

The NADAC for VERAPAMIL ER 180 MG TABLET has been published 242 times since Dec 8, 2021, and over the history we have for it it has declined 8.5%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1914 per EA
All-time high$0.2091 (Dec 15, 2021)
All-time low$0.1572 (Nov 20, 2024)
52-week high$0.1940
52-week low$0.1781
Median price$0.1896
Average price$0.1876
Largest weekly change-17.6% (Nov 20, 2024)
Weeks tracked242
Tracking sinceDec 8, 2021

Price History

1W

N/A

1M

N/A

3M

-0.9%

6M

-0.8%

1Y

+6.5%

3Y

+4.7%

5Y

N/A

All

-8.5%

Last surveyed Jul 22, 2026 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Lowest-Cost Alternatives

Save up to 0%

1 alternative • Same active ingredient

Frequently asked questions

What is the NADAC price of VERAPAMIL ER 180 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VERAPAMIL ER 180 MG TABLET, manufactured by Nivagen Pharmaceuticals Inc., is $0.1914 per EA (NDC 75834015805), effective Jul 22, 2026.

How has the price of VERAPAMIL ER 180 MG TABLET changed over time?

Over the history we have for it, the NADAC for VERAPAMIL ER 180 MG TABLET has declined 8.5%. It has been tracked across 242 weekly CMS publications since Dec 8, 2021.

What are the highest and lowest recorded NADAC prices for VERAPAMIL ER 180 MG TABLET?

Since Dec 8, 2021, the NADAC for VERAPAMIL ER 180 MG TABLET has ranged from a low of $0.1572 (Nov 20, 2024) to a high of $0.2091 (Dec 15, 2021), with a median of $0.1896 per EA.

Are there cheaper alternatives to VERAPAMIL ER 180 MG TABLET?

Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, VERAPAMIL ER 180 MG TABLET, is $0.1911 per EA — about 0% below VERAPAMIL ER 180 MG TABLET.

Who manufactures VERAPAMIL ER 180 MG TABLET?

VERAPAMIL ER 180 MG TABLET (NDC 75834015805) is labeled by Nivagen Pharmaceuticals Inc., and CMS classifies it as a generic product.